Most patients with allergic reactions to first COVID-19 vaccine receive second dose safely

most patients with allergic reactions to first covid 19 vaccine receive second dose safely

Sumary of Most patients with allergic reactions to first COVID-19 vaccine receive second dose safely:

  • Back to Healio Although the CDC lists a severe or immediate allergic reaction to the first dose of an mRNA COVID-19 vaccine as a contraindication for the second dose, a study found most individuals with a dose one reaction received dose two safely.
  • However, the results, published in The Journal of Allergy and Clinical Immunology: In Practice, also showed a limited role for excipient skin testing among patients with a reaction to the first dose.
  • 2021.06.010. The Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines include polyethylene glycol 2000 (PEG-2000), which has been examined as a possible cause of allergic reactions, though supportive evidence has been limited, Anna R.
  • Meanwhile, the Janssen adenovirus vector vaccine includes polysorbate 80. The researchers aimed to discover if there is a relationship between allergies to these excipients and allergic reactions to the vaccines.
  • They also evaluated the outcomes associated with excipient skin testing following allergic reactions to the first dose of the vaccine.
  • Out of 38,933 Moderna doses and 25,906 Pfizer-BioNTech doses administered between Jan.
  • 6 and March 3, 2021 at Mass General Brigham (MGB), the analysis included 80 patients (89% women;
  • Researchers assessed these patients using a risk stratification algorithm, which uses a clinical history with excipient skin testing to evaluate higher risk individuals.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.